Арилжаа Astellas Pharma Inc. - 4503 CFD

Арилжааны нөхцөл

• Төрөл: CFD
• Спред: 5.24
• Лонг позицын шөнийн санхүүжилтийн тохируулга: -0.01305%
• Шорт позицын нэг шөнийн санхүүжилтийн тохируулга: -0.00917%
• Шөнийн санхүүжилтийг тохируулах хугацаа: 22:00 (UTC)
• Валют: JPY
• Арилжаалсан доод хэмжээ: 1
• Маржин: 5.00%
• Хөрөнгийн бирж: Japan
• Арилжааны шимтгэл: 0%
• Баталгаат стопын шимтгэл: 1%

Гол үзүүлэлтүүд

• Өмнөх Хаах: 2241.85
• Нээх: 2241.35
• 1 жилийн өөрчлөлт: 50.95%
• Өдрийн диапазон: 2241.35 - 2266.82

Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceutical products worldwide. It offers XTANDI, an androgen receptor signaling inhibitor for the treatment of prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of overactive bladder (OAB); and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ transplant rejection. The company also provides Vesicare for OAB treatment; Eligard for prostate cancer treatment; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical collaboration agreement with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and Cytokinetics, Incorporated, as well as an agreement with BANDAI NAMCO Entertainment Inc. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.